INTRODUCTION {#s1}
============

Worldwide, there are more than 2.5 million new cervical and breast cancer cases, and the incidence and mortality of these cancers have increased over the past 30 years. Cervical and breast cancer are the leading cause of cancer-related deaths among females in low- and middle-income countries (LMIC), where women are disproportionately affected because of vulnerabilities related to gender inequality.^[@B1],[@B3]^ These increases have occurred even though population-based interventions, such as vaccination against human papillomavirus (HPV), screening with cervical cytology, visual inspection of cervix after applying acetic acid, testing for HPV DNA, breast examination, and mammography, are available.^[@B2]^

CONTEXT
-------

**Key Objective**Determine years of potential life lost as an indicator of premature deaths as a result of breast and cervical cancers.**Knowledge Generated**Screening has significantly reduced the mortality rate of cervical cancer, while breast cancer mortality remains unchanged.**Relevance**Findings show the positive impact of cervical cancer screening and indicate the need to strengthen breast cancer early detection awareness.

In Latin America, cervical cancer has reduced in incidence and mortality in recent years, but breast cancer has continued increasing and has higher mortality rates than in developed countries because most patients are diagnosed at more advanced stages of the disease. Both breast and cervical cancers in the region remain the main causes of mortality caused by malignant neoplasms.^[@B3],[@B4]^ In Guatemala, noncommunicable diseases produce more than one half of deaths in the country, with cancer accounting for approximately 10%. In 2013, the National Commission for the Prevention of Noncommunicable Diseases and Cancer was created by the Health Ministry with the aim of developing policies and actions to decrease the incidence and prevalence of the mortality and disability associated with noncommunicable diseases, which include breast and cervical cancers, with the latter having with its own designated program.^[@B5],[@B6]^ Cervical and breast cancers are the most common malignancies among females in the country and cause more than 2,000 deaths per year.^[@B5],[@B7],[@B8]^ Therefore, to assess the burden of breast and cervical cancers among Guatemalan women, we analyzed the years of potential life lost (YPLL) according to the mortality data available from the Guatemalan Health Ministry from 2012 to 2016.

METHODS {#s2}
=======

This is a study about the YPLL because of cervical and breast cancer in women in Guatemala. Data on mortality were obtained through the database of the Guatemalan Health Ministry, publicly available online in the Health Information System (SIGSA). We used the International Classification of Diseases (10th revision) codes for cervical (C53) and breast (C50) cancers for the data analysis.

For mortality and YPLL calculations, we used population data from SIGSA^[@B9]^ for each year. We divided the population into quinquennial age groups from 15 to \> 70 years. A maximum age of 70 years was chosen because of the projected life expectancy of Guatemala's population between 2000 and 2020.^[@B10]^

For YPLL, the calculations were made according to the formula:
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where 70 years is the cutoff age before death occurrence; *i* is the average number of YPLL because of death registered at the given age group; and d~i~ is the number of deaths in the i age group.

The YPLL rate was calculated as the quotient of the YPLL number and the number of inhabitants in Guatemala in the age group 20-70 years. The YPLL rate was calculated per 100,000 population.

The proportion mortality ratio was calculated according to the formula:
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The mortality rate was calculated according to the formula:
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A variable comparison was carried out using trend test analysis, analysis of variance, the Shapiro-Wilk test, and the 2-sample *t* test. All statistical tests were 2-sided and conducted at the 5% statistical significance level using R Studio and STATA version 12.

RESULTS {#s3}
=======

Cancer is a leading cause of death in Guatemala; there are between 21 and 23 cancer-related deaths per 100,000 habitants in the country ([Table 1](#T1){ref-type="table"}). During the study period from 2012 to 2016, 1,476 deaths resulting from breast and cervical cancers were reported in the population. From the total number of deaths as a result of these malignancies, 70.87% were associated with cervical cancer, even though the mortality for this disease had decreased from 18 to 10 deaths per 1 million habitants over a period of 5 years ([Table 1](#T1){ref-type="table"}; [Fig 1](#f1){ref-type="fig"}), with the highest mortality among patients older than 65 years of age ([Table 2](#T2){ref-type="table"}; Data Supplement). Conversely, the breast cancer mortality rate has kept steady, causing approximately 5 deaths per 1 million habitants in 2016 ([Table 1](#T1){ref-type="table"}; [Fig 1](#f1){ref-type="fig"}), with approximately 34% of breast cancer deaths reported among the patient group from 50 to 59 years of age ([Table 1](#T1){ref-type="table"}; Data Supplement).

###### 

Mortality of Cervical and Breast Cancers from 2012 to 2016
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![Mortality of cervical and breast cancers per 1,000,000 from 2012 to 2016.](JGO.19.00398f1){#f1}

###### 

Breast Cancer YPLL by Age Group
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Comparing the total YPLL between breast and cervical cancer among all age groups from 2012 to 2016, we found a mean of YPLL for cervical cancer of 2,960 (95% CI, 2,340.43 to 3,579.56) and a mean YPLL for breast cancer of 1,482 (95% CI, 1,193 to 1,770.59; *P* = .0003; [Tables 2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). The stratified analysis showed that between 2012 and 2016, YPLL caused by breast cancer has not changed dramatically over the years ([Table 2](#T2){ref-type="table"}; [Fig 2](#f2){ref-type="fig"}) with a rate of 18.04 YPLL per 100,000 habitants in 2016. In comparison, there has been a constant reduction in YPLL caused by cervical cancer, from 50.18 YPLL in 2012 to 29.19 YPLL by 2016 ([Table 3](#T3){ref-type="table"}; [Fig 3](#f3){ref-type="fig"}), mainly in women between 30 and 34 years of age in whom YPLL decreased from 600 to 112.50.
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Cervical Cancer YPPL by Age Group
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![Years of potential life lost because of cervical and breast cancers from 2012 to 2016.](JGO.19.00398f2){#f2}

![Breast and cervical cancer years of potential life lost per age group from 2012 to 2016.](JGO.19.00398f3){#f3}

DISCUSSION {#s4}
==========

Cancer is one of the leading causes of death worldwide, with more than 17 million new cases and 8.5 million cancer-related deaths per year. By 2030, cancer rates are predicted to increase to 23.6 million and more than 50% of the cases and 65% of the related deaths will occur in LMICs. It is estimated that one third of cancers could be prevented by reducing the main risk factors.^[@B11]^ Therefore, since 2010, Guatemala has made important efforts towards the reduction of cancer incidence and mortality, and this has resulted in the creation of the Health Ministry of the National Policy Against Cancer, which was followed by the creation of the National Commission for the Prevention of Noncommunicable Diseases and Cancer in 2013.^[@B6],[@B12]^ Our findings indicate that there is a significant reduction in the YPLL caused by cervical cancer in Guatemalan women, especially among women between 30 and 34 years of age, but this does not seem to be the same case for breast cancer. Some of the reasons for this difference could be a lack of awareness about the disease, inadequate access to medical resources and specialized cancer care, and economic constraints.^[@B13],[@B14]^

A 45% reduction in cervical cancer mortality after the implementation of the screening program is similar to the findings of a randomized study in rural India that included 131,746 women, in which the researchers documented a 35% reduction in cervical cancer mortality in patients who had been offered screening.^[@B15]^ In the process of defining the impact of a screening program on mortality in England, the estimate of the reduction in mortality was made using an incidence-based case-control study, and results indicated that screening prevented 69.7% of cervical cancer deaths.^[@B16]^ Similar results were reported in Canada, in which a study there found a 71% reduction in cervical cancer mortality between 1972 and 2006 after the implementation of screening program.^[@B17]^ Variations in the reduction in mortality have been identified in Latin American and Caribbean countries; limitations and barriers to access to screening services when compared with developed countries might explain these discrepancies.^[@B18]^

It is important to point out that our study did not analyze the incidence of breast and cervical cancer among the population, and with the data available we cannot determine the prevalence of these malignancies in Guatemala. In this context, even though breast cancer has a lower mortality rate, many women could be living chronically with the disease because of longer overall survival thanks to available new treatments.^[@B19]^ In comparison, women with cervical cancer usually have a shorter survival rate at any stage because of complications related to the tumor, such as hemorrhage and renal failure.^[@B19]^

The findings in this study indicate that the efforts made in cervical cancer screening are having the appropriate impact among Guatemalan women, significantly reducing the mortality caused by this malignancy, but screening for breast cancer must improve through a greater awareness of the disease and better access to women at risk.
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